Introduction of the new HTA process

Executive Summary

In 2019, Japan introduced a new HTA process for drugs and medical devices selected by the Chuikyo. The selection criteria exclude rare disease and paediatric drugs. The HTA is currently only used for product price adjustments rather than reimbursement and pricing decision making.